Agios Pharmaceuticals focuses on developing small-molecule medicines for cancer and rare genetic disorders of metabolism, with a precision approach to genetically or biomarker-defined patient populations. They seek proof of concept early in clinical development and have multiple investigational therapies in development. Their most advanced drug candidate is mitapivat, a PKR activator being evaluated for the treatment of hemolytic anemias. The company values teamwork, diversity, and delivering extraordinary results.